HC Wainwright reiterated their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Caribou Biosciences’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.79) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.53) EPS and FY2025 earnings at ($2.00) EPS.
A number of other research analysts have also recently commented on the stock. Truist Financial restated a buy rating and set a $19.00 price target on shares of Caribou Biosciences in a research note on Thursday, May 16th. Royal Bank of Canada restated an outperform rating and set a $14.00 target price on shares of Caribou Biosciences in a research report on Wednesday, August 7th. Finally, Evercore ISI cut Caribou Biosciences from an outperform rating to an inline rating and lowered their price target for the company from $13.00 to $3.00 in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $15.00.
Caribou Biosciences Trading Up 0.5 %
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. The firm had revenue of $3.46 million for the quarter, compared to analyst estimates of $3.31 million. Caribou Biosciences had a negative net margin of 345.05% and a negative return on equity of 33.42%. Sell-side analysts predict that Caribou Biosciences will post -1.8 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Caribou Biosciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new stake in shares of Caribou Biosciences during the first quarter worth $558,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Caribou Biosciences during the 4th quarter worth about $253,000. Vanguard Group Inc. grew its holdings in Caribou Biosciences by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock worth $21,129,000 after acquiring an additional 148,751 shares during the last quarter. Wellington Management Group LLP increased its position in Caribou Biosciences by 57.7% in the 4th quarter. Wellington Management Group LLP now owns 314,080 shares of the company’s stock valued at $1,800,000 after acquiring an additional 114,975 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Caribou Biosciences in the first quarter worth about $113,000. 77.51% of the stock is owned by institutional investors and hedge funds.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Recommended Stories
- Five stocks we like better than Caribou Biosciences
- What is the Shanghai Stock Exchange Composite Index?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 8/12 – 8/16
- How to Use High Beta Stocks to Maximize Your Investing Profits
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.